·Week of August 10-14, 2026

Clinical Trials Brief | August 17, 2026

This week: WHO moving to a randomised Phase 3 trial of Ervebo against Bundibugyo Ebola as the outbreak passed 4,600 confirmed cases, FDA granting the first myeloma accelerated approval based on MRD negativity, EMA opening its reliance pilot for post-authorisation changes to more companies, new immune globulin lots withdrawn for hypersensitivity reactions, and Jazz agreeing to buy Actio Biosciences for up to $1.32 billion.

WHO moves to a randomised Phase 3 trial of Ervebo against Bundibugyo Ebola as the outbreak passes 4,600 confirmed cases

What changed

WHO's Technical Advisory Group recommended in early August that Ervebo, the only licensed Ebola vaccine, be prioritised for a randomised clinical trial against Bundibugyo virus disease in the Democratic Republic of the Congo. According to the WHO statement as reported, experts identified no safety concerns with Ervebo for contacts of confirmed cases, but stressed that its effectiveness against Bundibugyo had not been established. A vaccine developed specifically against Bundibugyo would remain preferred, but data on such candidates were not yet available. A Mappr summary of WHO updates reports that on August 12 WHO said it was about to submit a protocol to DRC regulators that would randomise contacts of confirmed cases to vaccine or placebo. WHO's Disease Outbreak News of August 14 reported 4,665 confirmed cases and 2,184 deaths in the DRC, a case fatality rate of 46.8%. UN News reported that the first Bundibugyo-specific vaccine candidate entered a Phase 1 trial in the UK on July 24, with another starting in Canada.

Why it matters

With treatment (PARTNERS) and prophylaxis (EBO-PEP) trials already running, a vaccine trial completes the research response. The design question is the hard one. A placebo-controlled trial of a licensed vaccine, even one licensed for a different species, during an outbreak with a case fatality rate near 50% raises real ethical tension. The scientific case is that Ervebo's effect against Bundibugyo is genuinely unknown, so a placebo arm may be the only way to find out. Ring-vaccination trials in earlier outbreaks used delayed-vaccination comparators instead, and how this protocol handles that choice will be closely watched by ethics committees.

Takeaway

For outbreak trialists, the main lesson is preparedness: UN News quoted WHO's R&D Blueprint lead saying trials started faster this time because protocols had been written before the outbreak was declared. Preparedness work on master protocols and pre-agreed designs is what turns into enrolled patients when an outbreak begins.

FDA grants the first myeloma accelerated approval based on MRD negativity, approving iberdomide four days early

What changed

On August 13, 2026, FDA granted accelerated approval to Zenbexus (iberdomide, Bristol Myers Squibb) with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Efficacy was evaluated in EXCALIBER-RRMM, a two-stage, randomised, open-label trial that enrolled 939 patients (279 in stage 1 and 660 in stage 2) and compared the iberdomide regimen with daratumumab, bortezomib and dexamethasone. The major efficacy outcome was MRD-negative complete response at any time: 41% (95% CI, 34-48) with the iberdomide regimen versus 21% (95% CI, 15-27) with the comparator (p<0.0001). The International Myeloma Foundation describes this as the first accelerated approval in myeloma based on MRD as an early endpoint. The PDUFA date had been August 17. Because of embryo-fetal toxicity, iberdomide is available only through a REMS programme.

Why it matters

This is the first use of a regulatory pathway the myeloma field has been building for years: the i2TEAMM analyses, the unanimous ODAC vote and FDA's January 2026 draft guidance on MRD and complete response as accelerated-approval endpoints. It means a randomised trial can support approval on deep response years before progression-free or overall survival matures. Iberdomide is also the first approved CELMoD, a new class of cereblon modulators. As with any accelerated approval, the long-term value depends on confirmatory evidence of clinical benefit.

Takeaway

Myeloma sponsors should build MRD assessment into Phase 3 designs as a prespecified, centrally assessed endpoint with standardised timing and assay sensitivity (10^-5 here). MRD sample logistics, including bone marrow collection compliance and central lab turnaround, now sit on the regulatory critical path.

Sources

This item is grounded in FDA's approval notice of August 13, 2026 as summarised by the Oncology Nursing Society, and reporting by Targeted Oncology and the International Myeloma Foundation.

EMA opens its reliance pilot for post-authorisation changes to more companies, extending EU assessments to non-EU regulators

What changed

On August 13, 2026, EMA published a dedicated guidance page explaining how pharmaceutical companies can apply to join its pilot programme for reliance on post-authorisation changes. The pilot lets companies submit post-authorisation changes simultaneously to multiple countries outside the EU, with national authorities relying on EMA's assessment to inform their own decisions. Interested companies contact EMA with an overview of the proposed pilot and details of the changes. Pilots begin with a kick-off meeting held alongside WHO, where the applicant gives national authorities the details, timelines and logistics, and the national authorities then assess and decide. EMA says the content was previously on its pilot page and that tracking of updates begins in August 2026.

Why it matters

Post-approval changes, such as manufacturing site transfers, specification updates and new safety information, are a huge and often invisible regulatory workload. A single change can take years to approve across dozens of countries, which leaves products with different versions in different markets. Reliance on EMA's assessment, coordinated with WHO, could shorten that tail considerably, especially in low- and middle-income countries. It fits the wider push for reliance seen this summer, including WHO's draft GCP guideline and Health Canada's ministerial reliance order.

Takeaway

Regulatory operations teams managing global lifecycle changes for EU-authorised products should consider the pilot for changes affecting many non-EU markets. For clinical teams, faster harmonisation of safety-related label updates across countries also reduces inconsistencies between reference safety information and local labels in multinational trials.

Sources

This item is grounded in EMA's guidance page for the pharmaceutical industry on reliance for post-authorisation changes, published August 13, 2026.

More immune globulin lots are withdrawn over hypersensitivity reactions, a reminder to capture lot numbers in trials

What changed

On August 14, 2026, FDA updated its notice on voluntary withdrawals of immune globulin intravenous (IGIV) and subcutaneous (IGSC) lots because of a higher rate of allergic or hypersensitivity reactions, some considered medically significant. According to AABB, the additions were one lot each of Gammaked and Gamunex-C (Grifols) and two lots of Yimmugo (Biotest AG). Grifols initiated the Gammaked withdrawal on August 11 and Biotest the Yimmugo withdrawal on August 13. FDA advises facilities to check their stock immediately, stop using affected lots and return them for replacement. Hypersensitivity and anaphylactic or anaphylactoid reactions are known risks with immune globulin products, and earlier withdrawals for the same reason took place in 2022 and 2025.

Why it matters

These are lot-level signals, detected because reaction rates for specific lots stood out from the background rate of a known risk. That kind of signal is only detectable if lot numbers are captured. Immune globulin is widely used in clinical research: as investigational product in CIDP, ITP and immunodeficiency trials, as background therapy, and as rescue or concomitant medication in many others. In trials, a hypersensitivity reaction to a concomitant IVIG lot can easily be attributed to the study drug if the lot is not recorded.

Takeaway

Where immune globulin is a concomitant or background therapy, protocols and eCRFs should capture product name and lot number, not just "IVIG". Sites should check affected lots against current stock and trial records, and medical monitors should review recent hypersensitivity events for exposure to withdrawn lots before assigning causality to the investigational product.

Sources

This item is grounded in FDA's August 14, 2026 notice as summarised by AABB and Drugs.com, and Express Scripts notices on the Gammaked and Yimmugo withdrawals.

Jazz agrees to buy Actio Biosciences for up to $1.32 billion, adding a precision epilepsy drug as private biotech buyouts surge

What changed

On August 10, 2026, Jazz Pharmaceuticals agreed to acquire Actio Biosciences in a deal worth up to about $1.32 billion, according to BioPharma Dive, with $820 million paid upfront. Actio's lead asset, ABS-1230, is a KCNT1 inhibitor in development for rare, genetically defined epilepsy. BioPharma Dive placed the deal within a broader upswing in buyouts of private biotechs this year. The same week brought several other licensing deals, including Sobi's agreement for Innate Pharma's lacutamab and Menarini's licence of Gan & Lee's GLP-1 agonist, according to DIMA Biotechnology's deal tracker.

Why it matters

KCNT1-related epilepsy is a severe developmental and epileptic encephalopathy defined by a single gene, which makes it a good fit for precision medicine but a hard one for trials. Patient populations are small, mostly paediatric and spread across many countries, and endpoints such as seizure frequency need careful diary-based measurement. For an acquirer, the value depends on running a registrational programme in a very small population, which links directly to FDA's recent openness to single-trial and rare-disease evidence packages.

Takeaway

Rare-epilepsy trial teams should expect more competition for the same small, genetically confirmed populations as larger sponsors enter. Genetic testing networks, patient registries and natural history data become strategic assets for recruitment and for external controls.

Sources

This item is grounded in BioPharma Dive's deal coverage of August 10, 2026 and the DIMA Biotechnology deal tracker.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.